Oklahoma City, OK -- Cytovance® Biologics, Inc., a leading full-service contract manufacturer of mammalian and microbial biologics, announced today that it will expand its current mammalian production capabilities to include a 1,000L SUB bioreactor, a 5,000L stainless steel bioreactor and an automated fill/finish line.
Cytovance® Biologics, a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, welcomes Maria Lopez as the Vice President of Quality.
“With over 15 years of experience in the biopharm industry, Maria brings a depth of experience in medical device and biologics manufacturing,” said Darren Head, President and Chief Executive Officer of Cytovance Biologics. “We are very fortunate to have such a well-seasoned and experienced executive join our team. Maria’s knowledge and leadership skills will be tremendous assets to the Company.”
Norwich, New York – Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has been recognized as Manufacturer of the Year by the Chenango County Chamber of Commerce. The award presentation occurs at a time when Norwich is celebrating 125 years of continuous operation for pharmaceutical manufacturing.
Tyson Popp, vice president, global sourcing and Americas supply chain, West Pharmaceutical Services, Inc., has been formally elected president of the Drug, Chemical & Associated Technologies Association (DCAT) by the membership. He assumed the office on November 1, 2012. Also elected to serve as officers were Lyra Myers, associate director and value creation agent, Genentech, George Svokos, senior vice president, product and portfolio management, Teva Pharmaceuticals USA, Inc. and Folker Ruchatz, vice president, global business management custom synthesis, BASF.
CHARLOTTE, NC - September 12, 2012 - Metro Charlotte-based EI, A Pharmaceutical SolutionWorks™ has signed agreements with European-based professors and technologists for the exclusive worldwide license of a novel class of sphingolipids. Sphingolipids are found in the extracellular spaces of the startum corneum, where they play a critical role in strengthening the barrier functio of the skin, promoting moisture retention and inccreasing elasticity of the skin.
Laying the Groundwork for Your Governance, Risk and Compliance (GRC) Journey
Learn from Johnson & Johnson about the foundational elements needed to meet your broader GRC goals
Presented By: Isabel Smith, Director of IA & eGRC Program, Johnson & Johnson, Inc and Shellye Archambeau, CEO, MetricStream
Date: Wednesday June 27, 2012
Time: 8 am Pacific | 11 am Eastern
Duration: 1 hour
Link to register:
In this changing regulatory environment, it becomes important for organizations to start thinking about an enterprise-wide initiative that can bring order and structure to the complexity of complying with industry specific regulations (such as FDA, HIPAA, HITECH) and cross-industry mandates (such as the FCPA, UK Anti-Bribery Act, IT Privacy and Security Laws, SOX). This initiative, called the Enterprise GRC (Governance, Risk & Compliance) Strategy, involves tracking regulatory changes, implementing controls, managing risks, carrying out audits, and defining and ensuring policy conformance in a unified manner.
Streamlines Sales and Marketing Organization and Hires Marketing Agency to Drive Increased Sales and Brand Awareness
Albany, NY (April 24, 2012)–AMRI (NASDAQ: AMRI) announced today key changes in its Business Development and Marketing functions. AMRI’s separate North American Discovery and Development teams are being combined into one functional sales organization, under the leadership of Christopher Conway, who has been promoted to Vice President, Business Development, North America. This creates a seamless integration of business development and marketing efforts in North America with the goal of optimizing territory cross-selling opportunities and customer service.
DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V. (NYSE, Euronext: DSM KON) and Agennix AG (Frankfurt Stock Exchange: AGX) have signed a new contract under which DSM will continue to manufacture talactoferrin for Agennix at commercial levels.
Pharmatek's focus on pharmaceutical chemistry development, combined with their state-of-the-art HP/C facilities, ensures their customer's molecules move efficiently from discovery to clinical trials.
Click here to download whitepaper.
Want more? Visit...